Cancer patients get extended access to promising drugs
NCT ID NCT02632994
Summary
This study allows cancer patients who benefited from previous Eli Lilly drug trials to continue receiving the study medication after those trials conclude. It focuses on monitoring the long-term safety of these treatments. Only patients who were already receiving the drug in a completed Lilly study and showing benefit are eligible to participate.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fort Wayne Oncology & Hematology
AVAILABLEFort Wayne, Indiana, 46804, United States
Contact Phone: •••-•••-••••
Contact
-
Sarah Cannon Cancer Center
AVAILABLENashville, Tennessee, 37203, United States
Contact Phone: •••-•••-••••
Contact
-
UCLA Medical Center
AVAILABLETorrance, California, 90505, United States
Contact Phone: •••-•••-••••
Contact
Conditions
Explore the condition pages connected to this study.